Author(s)

Xiaoyue Wen, Yongqin Zhou

Corresponding Author

Yongqin Zhou

Abstract

Amyotrophic Lateral Sclerosis is a chronic progressive neurodegenerative disorder. Because of its low incidence, people also have a limited understanding of its onset and treatment. The patient with this disease has a motor nerve that causes the muscles of the body to become weak. About 20% of Amyotrophic Lateral Sclerosis patients are genetically ill. Some studies have shown that the excitatory amino acid neurotransmitter glutamate may also be involved in pathogenesis. At the same time, researchers at the University of Michigan found that persistent environmental pollutants measured in the blood were significantly associated with Amyotrophic Lateral Sclerosis and may also be indicative of disease risk factors for Amyotrophic Lateral Sclerosis. However, the cause of the disease has not yet been determined, and the medical profession has not found a way to cure the disease. The average survival rate of patients with Amyotrophic Lateral Sclerosis after diagnosis was 3-5 years. The Amyotrophic Lateral Sclerosis specific drug is being developed. The anticoagulant riluzole appears to slow the progression of amyotrophic lateral sclerosis and may improve the survival rate of patients with cancer, and edaravone also shows modest efficacy.

Keywords

Amyotrophic Lateral Sclerosis; Mechanism; Pathophysiology; Mental Behavior; Treatment; Intestinal Microbes